Functional Proteomics Group, Osaka University Graduate School of Frontier Biosciences, Osaka, Japan.
Proteomics Clin Appl. 2007 Feb;1(2):185-91. doi: 10.1002/prca.200600497. Epub 2007 Jan 22.
To screen for autoantibodies associated with systemic lupus erythematosus (SLE), we used proteomic approaches combining 2-D PAGE and Western blot analysis, followed by protein identification by LC-MS/MS analysis, resulting in the identification of aldolase A as a novel autoantigen in SLE. ELISA showed the prevalence of anti-aldolase A antibodies to be 29.3% in SLE, 8.2% in rheumatoid arthritis, 18.1% in polymyositis and absent in healthy controls. Furthermore, 43.4% of SLE patients suffering from nephritis showed anti-aldolase A autoantibodies, which was significantly higher than the prevalence for those without nephritis (11.1%). In lupus nephritis, there are few reliable diagnostic methods, other than urinalysis. Therefore, these results indicate that autoantibodies against aldolase A may serve as an alternative clinical biomarker of SLE associated with nephritis.
为了筛选与系统性红斑狼疮（SLE）相关的自身抗体，我们使用了结合二维电泳和 Western blot 分析的蛋白质组学方法，随后通过 LC-MS/MS 分析进行蛋白质鉴定，结果鉴定出醛缩酶 A 是 SLE 中的一种新的自身抗原。ELISA 显示抗醛缩酶 A 抗体在 SLE 中的患病率为 29.3%，在类风湿关节炎中为 8.2%，在多发性肌炎中为 18.1%，在健康对照组中则不存在。此外，43.4%患有肾炎的 SLE 患者表现出抗醛缩酶 A 自身抗体，这明显高于没有肾炎的患者（11.1%）。在狼疮肾炎中，除了尿液分析外，很少有可靠的诊断方法。因此，这些结果表明，针对醛缩酶 A 的自身抗体可能成为与肾炎相关的 SLE 的另一种临床生物标志物。
